Chlorphentermine

Chlorphentermine
Systematic (IUPAC) name
1-(4-chlorophenyl)-2-methylpropan-2-amine
Clinical data
Routes of
administration
Oral, Insufflated, Rectal
Legal status
Legal status
Pharmacokinetic data
Biological half-life 40 hours
Excretion Renal
Identifiers
CAS Number 461-78-9 N 151-06-4
ATC code A08AA (WHO)
PubChem CID 10007
DrugBank DB01556 YesY
ChemSpider 9613 YesY
UNII NHW07912O7 YesY
KEGG C07559 YesY
ChEMBL CHEMBL1201269 N
Synonyms p-Chloro-α,α-dimethylphenethylamine
Chemical data
Formula C10H14ClN
Molar mass 183.68 g/mol
 NYesY (what is this?)  (verify)

Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is a serotonergic appetite suppressant of the amphetamine family. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant phentermine,[1] which is still in current use.

Chlorphentermine acts as a highly selective serotonin releasing agent (SRA).[2] It is not a psychostimulant and has little or no abuse potential, but is classed as a Schedule III drug in the USA due mainly to its similarity to other appetite suppressants such as diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.[3]

See also

References

  1. Gylys JA, Hart JJ, Warren MR. Chlorphentermine, a new anorectic agent. Journal of Pharmacology and Experimental Therapeutics. 1962 Sep;137:365-73.
  2. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.". Synapse 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
  3. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75.



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.